CriticalReversible MAO-A inhibitor (RIMA)×Fixed-dose combination: weak opioid with SNRI activity plus non-opioid analgesic
Updated · Methodology
Mechanism
Moclobemide reversibly inhibits monoamine oxidase (MAO), mainly type A, and slows the breakdown of noradrenaline, dopamine and serotonin (moclobemide summary of product characteristics, SmPC, section 5.1). Tramadol is an opioid that also relieves pain by inhibiting neuronal noradrenaline reuptake and increasing serotonin release (tramadol/paracetamol SmPC, section 5.1). Because of the risk of serotonin syndrome, the Spanish tramadol/paracetamol SmPC lists selective MAO type A inhibitors among contraindicated drugs by extrapolation from non-selective MAO inhibitors (section 4.5). The moclobemide SmPC contraindicates tramadol by name (sections 4.3 and 4.5). According to the US Food and Drug Administration (FDA) tramadol/acetaminophen label, MAO inhibitors combined with opioids may cause serotonin syndrome or opioid toxicity with respiratory depression and coma (section 7). The documents say nothing about a separate interaction between paracetamol and moclobemide.
Symptoms
With tramadol and monoamine oxidase (MAO) inhibitors, serotonin syndrome presents with diarrhoea, fast heart rate, heavy sweating, tremor and confusion, even coma (tramadol/paracetamol summary of product characteristics, SmPC, section 4.5). According to the US Food and Drug Administration (FDA) tramadol/acetaminophen label, signs also include agitation, hallucinations, labile blood pressure, high temperature, overactive reflexes (hyperreflexia), poor coordination, rigidity, nausea and vomiting (section 5.10). Symptoms usually start within several hours to a few days of combined use, but may start later (FDA label, section 5.10). Interactions between MAO inhibitors and opioids may also present as opioid toxicity with respiratory depression and coma, and tramadol taken with MAO inhibitors increases the risk of seizures (FDA label, sections 5.11 and 7).
Management
The combination is contraindicated. Tramadol is on the list of drugs contraindicated with moclobemide (moclobemide summary of product characteristics, SmPC, sections 4.3 and 4.5). The Spanish tramadol/paracetamol SmPC contraindicates monoamine oxidase (MAO) inhibitors and their use within the last two weeks, and it names selective MAO type A inhibitors (sections 4.3 and 4.5). The US Food and Drug Administration (FDA) tramadol/acetaminophen label also contraindicates it with MAO inhibitors or within 14 days of stopping them (sections 4 and 7). Start tramadol/paracetamol no earlier than two weeks after the last dose of moclobemide (tramadol/paracetamol SmPC, sections 4.3 and 4.5, and FDA label, section 7). No document gives an interval for the opposite order, when moclobemide is started after tramadol/paracetamol. According to the FDA label, do not start an MAO inhibitor while the patient is taking tramadol/acetaminophen, and warn the patient not to combine it with any drug that inhibits MAO (section 17). Switching to another opioid does not always remove the risk. With moclobemide, morphine, fentanyl and codeine may need a dose adjustment, and buprenorphine calls for caution because of the risk of serotonin syndrome (moclobemide SmPC, sections 4.4 and 4.5). If serotonin syndrome is suspected, stop tramadol/paracetamol (FDA label, section 5.10). The Spanish tramadol/paracetamol and moclobemide SmPCs advise considering a dose reduction or stopping treatment, depending on how severe the symptoms are (section 4.4 of both). According to the tramadol/paracetamol SmPC, the condition usually improves quickly once the serotonergic drugs are stopped (section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Moclobemida, Manerix 300 mg (nº registro 60824) (2025)– AEMPS, CIMA, nº registro 60824 (Manerix 300 mg comprimidos recubiertos con película), revisión 06/2025, secciones 4.3, 4.5, 5.1 y 5.2
- AEMPS: Ficha técnica: Tramadol/Paracetamol, Zaldiar 37,5 mg/325 mg (nº registro 65149), sección 4.5 (2026)– AEMPS, CIMA, nº registro 65149 (Zaldiar 37,5 mg/325 mg comprimidos recubiertos con película, Grünenthal Pharma), revisión 02/2026, secciones 4.2, 4.3, 4.4, 4.5 y 4.9
- FDA: Tramadol hydrochloride and acetaminophen tablets (Amneal) prescribing information (2026)– FDA, DailyMed setid d51600e2-2f73-483c-9b2e-f142bafff16d (Amneal Pharmaceuticals of New York), versión 34, efectiva 01/2026, Boxed Warning, secciones 5.3, 5.10, 5.11 y 7